Calluna Pharma
2 known investors
Completed patient enrollment in its Phase 2 AURORA trial.
Investors · 2
Competitors · 3
by search overlapBioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Laguna Biosciences Website3 shared keywordsLaguna Bio develops cancer therapeutics using engineered, attenuated microbial vectors through its QUAIL and IBIS platforms, which activate innate immune responses and innate T cells inside the body to attack tumors. Its pipeline targets AML and other high-risk leukemias, multiple myeloma, sarcoma, colorectal cancer, and additional solid tumor, inflammatory, and infectious disease indications.
Contract3 shared keywordsContract Pharma is a trade media publication covering the pharmaceutical and biopharmaceutical industry, with a focus on contract development and manufacturing (CDMO) topics. It provides industry news, magazine issues, expert interviews, webinars, whitepapers, company directories, and event coverage for professionals in the pharma and biopharma sector.
Companies competing with Calluna Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Calluna Pharma do?
- Completed patient enrollment in its Phase 2 AURORA trial.
- Who are Calluna Pharma's investors?
- Calluna Pharma's investors include P53 Invest, Sarsia Management AS.